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Previewsestablish a replicative niche (Rejman
Lipinski et al., 2009). Conversely,
Rab11 actively limits the noxious perme-
abilization effect of small pore-forming
toxins (Los et al., 2011). Cells achieve
this notably by expelling microvilli by a
Rab11-dependent mechanism, likely
requiring vesicle fusion. Rab11 also con-
trols the trafficking of the Toll-like recep-
tor 4 (TLR4) from endocytic recycling
compartments to phagosomes contain-
ing Escherichia coli. This allows a local
stimulation of TLR4 together with inter-
feron regulatory factor 3 (IRF3) for
robust production of interferon-g (Huse-
bye et al., 2010). Collectively, these
studies point to a critical function of
Rab11 signaling in host pathogen
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In this issue ofCell Host &Microbe, Varble et al. (2013) engineer a library of RNA viruses to express small inter-
fering RNAs and couple this with the power of virus evolution and selection to screen for host genes that when
silenced resulted in greater viral infection in vivo.Over the last five years, a variety of
screening methods have been used to
identify host factors that restrict viral
infection. Some investigators have used
genome-wide screening approaches,
whereas others have targeted specific
antiviral pathways, including the type I
interferon (IFN) response. Experimentally,
these screens have relied on short hairpin
RNA-based gene silencing or ectopic
gene expression largely in transformed
cell culture models of virus infection. In
gene silencing approaches, virus infec-
tivity is enhanced when expression of
restriction factors is diminished. In the
context of treating cells with exogenous
IFN, gene silencing can define the relativecontribution of individual interferon-
stimulated genes (ISGs) to the host anti-
viral responses. In ectopic expression
screens, particularly of genes in the IFN
signaling and effector pathway, host
factors that are sufficient to protect cells
from virus infection have been revealed.
Each screening method has strengths
and limitations. In genome-wide siRNA
screening approaches, an underlying
assumption is that a restriction factor will
be expressed basally at levels that are
sufficient to control an incoming virus.
The identification of the antiviral activity
of IFITM gene family members is a suc-
cessful example of this strategy (Brass
et al., 2009). Other genome-wide siRNAscreens have been performed in the
context of IFN treatment and uncovered
numerous putative host restriction fac-
tors, many of which regulate cellular
antiviral responses even though they are
not induced by IFN (Fusco et al., 2013;
Zhao et al., 2012). Two screens that
specifically targeted the IFN pathway by
silencing a comprehensive panel of ISGs
identified novel host factors that had
direct effector functions or regulated IFN
response pathways (Li et al., 2013; Metz
et al., 2012). In addition to gene silencing
strategies, ectopic expression screens
also have identified ISGs that inhibit virus
infection. When hundreds of ISGs were
tested for their ability to suppress virusptember 11, 2013 ª2013 Elsevier Inc. 229
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Previewsinfection (Liu et al., 2012; Schoggins et al.,
2011), many known and novel genes with
antiviral activity were revealed, which has
helped to elucidate the complex nature of
the IFN response against RNA and DNA
viruses.
Identifying the full complement of
cellular host restriction factors against
viruses likely will require the continued
and cumulative effort of both loss-of-
function and gain-of-function ap-
proaches. Perhaps not surprisingly, the
strongest hits from most screens to date
have been genes that regulate antiviral
pathways. Nonetheless, some putative
and novel direct antiviral effectors have
been identified (Li et al., 2013; Liu et al.,
2012; Metz et al., 2012; Schoggins et al.,
2011), with numerous laboratories now
pursuing their respective mechanisms of
action. The relevance of several ISGs
identified in cell culture screens (e.g.,
Ifitm3, Ifit1, Ifit2, Rsad2/viperin, Irf1,
and Ch25h, among others) has been
confirmed in vivo with demonstrable
virological phenotypes observed in mice
with targeted gene deletions. Given the
resources required to generate transgenic
mice, novel gene screening strategies
that can rapidly assess antiviral activity
in vivo would be particularly useful in
identifying additional and physiologically
relevant host restriction factors. In this
issue, the tenOever laboratory has ad-
dressed this need. Varble et al. (2013)
applied an innovative screening strategy
to identify novel host genes that restrict
viral infection in an in vivo setting.
The authors performed a large-scale
siRNA screen in the context of an infection
by Sindbis virus (SINV), a model arthrito-
genic alphavirus of the Togaviridae family.
Rather than introduce genes ectopically
or silence them by transfection of siRNA
or plasmid expression of shRNAs, the
authors constructed libraries of individual
SINV, each encoding a distinct artificial
microRNA (amiRNA). Unlike shRNAs,
which are fully complementary hairpins
that bypass the need for the cell’s micro-
processor, amiRNAs are Drosha-depen-
dent substrates that mimic endogenous
hairpins and feed into the host small
RNA machinery to produce gene-specific
siRNAs (tenOever, 2013). Proof-of-princi-
ple studies were performed in cell culture
with SINV encoding amiRNAs against
GFP or the antiviral sensor RIG-I to con-
firm accurate processing of the amiRNA,230 Cell Host & Microbe 14, September 11, 2reduction in target gene expression, and
enhanced viral infection (RIG-I only). The
authors then performed experiments
with the SINV library in mice. Two days
after subcutaneous inoculation, virus
was isolated from the spleen and sub-
jected to deep sequencing; this revealed
a clear enrichment of particular amiRNAs
in the viral genome. The significance of
selecting SINV containing individual
amiRNAs was confirmed by recloning
the hairpin into the parental SINV, infect-
ing recombinant viruses into naive mice,
and showing they retained selection and
replicated to higher levels compared to
the parent virus.
The authors performed several inde-
pendent and unbiased screens using
SINV libraries of 10,000 independent
amiRNAs and, after deep sequencing,
looked for target genes that were
enriched. After identifying approximately
25 of the top ‘‘hits,’’ the authors selected
two siRNA target genes, Zfx and Mga,
for detailed validation and mechanism of
action studies. These two genes were
previously uncharacterized with respect
to viral infection, conferred the greatest
replication advantage in vivo, and were
enriched in the majority of independent
screens. Using a variety of biochemical
and cell-based assays, the authors pro-
vide compelling evidence that both Zfx
and Mga are transcriptional factors that
influence ISG induction at different stages
of the signaling pathway. Consistent with
a more general transcriptional effect, the
impact of reducing expression of these
genes was not specific to SINV, as
silencing or deletion of Zfx and Mga also
enhanced infection of influenza A virus,
an unrelated segmented negative strand
RNA virus of the Orthomyxoviridae. Inter-
estingly, individual genes defined previ-
ously as alphavirus restriction factors in
cell culture or in vivo (e.g., Bst2, Rsad2/vi-
perin, Zc3hav1/ZAP, Isg20, and Parp12)
were not identified in this screen.
By coupling RNA interference with virus
replication and selection in vivo, the
authors defined a novel set of host
genes that, when silenced, resulted in
enhanced infection in a relevant context.
This strategy worked for several reasons:
(1) although RNA viruses tend to select
against exogenous genomic insertions
that may inherently compromise fitness,
the selective pressure to reduce expres-
sion of antiviral genes was greater, and013 ª2013 Elsevier Inc.thus the embedded amiRNA targeting
inhibitory genes were retained; (2) SINV
replicates rapidly in the absence of
immune pressures (i.e., propagation in
Vero or BHK21 cells lacking cell-intrinsic
immunity), but is inhibited efficiently by
the antiviral effects of type I IFN or host
defense genes, which allows a strong
and selective pressure to silence inhibi-
tory genes; and (3) SINV, in contrast to
other alphaviruses (e.g., Venezuelan and
Eastern equine encephalitis viruses), is
relatively attenuated in mice, possibly
because its viral gene products do not
efficiently antagonize and evade host
innate immune restriction pathways.
Thus, selection and enhanced replication
of SINV variants in the context of silencing
individual host genes can be observed.
The power of this RNA interference
screen is its ability to identify host restric-
tion factors in the context of virus infection
in vivo by relying on virus competition and
selection. For SINV, this strategy yielded a
distinct set of target inhibitory genes
compared to conventional gene silencing
or ectopic expression screens. One can
imagine the application of this screen in
different contexts to address unique
questions of host antiviral defense.
Screens could be performed ex vivo in
specific primary cell types (neurons, den-
dritic cells, macrophages, fibroblasts, or
epithelial cells) to identify cell type-spe-
cific genes that restrict SINV infection.
Alternatively, infection screens with SINV
could be repeated in immunocompro-
mised mice (i.e, Stat1/ or Ifnar/) to
focus on inhibitory genes that function
independently of IFN signaling. Selected
smaller libraries of SINV-miR targeting
specific candidate effector ISGs could
be developed to identify the hierarchy of
antiviral control in vivo. Finally, this gain-
of-function selection approach likely can
be applied to other RNA or DNA viruses
to clarify the host-pathogen interface
by identifying novel host factors that
inhibit replication, affect tropism, impact
the establishment of persistence, and
attenuate pathogenesis and virulence.
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